Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
The two windows in practice: Whichever ends first determines the safe-use period
Key risks include pancreatitis, gallbladder disease, potential thyroid C-cell tumours, and altered levothyroxine requirements due to weight changes
Neither injection is a weight-loss treatment
In Phase 3 clinical trials, retatrutide has been studied as a once-weekly injection, starting at 2mg once weekly and increasing gradually every four weeks
1 This comes after Hims & Hers was barred from selling compounded GLP-1 medications earlier this year
US$ 25.05
US$ 23.59
:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)
US$ 23.39
